Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease

Erosive Reflux Disease Clinical Trial

Official title:
A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Erosive Reflux Disease

Status Completed

Clinical Trial Summary

This study is designed to evaluate the efficacy and safety of Tegoprazan 50mg, compared to Lansoprazole 30mg in patients with healed erosive reflux disease confirmed by endoscopy following oral administration once daily(QD) of 2 weeks or 4 weeks.

Clinical Trial Description

This is a double blind, radomized, active-controlled, phase 4 study. Subjects will be randomly assigned to one of the two treatment groups (Tegoprazan 50mg, Lansoprazole 30mg) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05267743
Study type	Interventional
Source	HK inno.N Corporation
Contact
Status	Completed
Phase	Phase 4
Start date	February 16, 2021
Completion date	May 25, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04309916` - Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance	Phase 4
	Completed	`NCT01797939` - Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients	N/A